J. Mark Sloan, MD
Associate Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Hematology & Medical Oncology

MD, Yale University School of Medicine
BS, Haverford College

Pronouns: he/him/his



Factotum hematologist at Boston Medical Center
Associate Professor at Chobanian and Avedisian School of Medicine.
Program director for the hematology/oncology fellowship at Boston University.
I see patients with a variety of benign and malignant blood disorders.
I have particular research interests in AL Amyloidosis, HTLV-1 associated leukemia/lymphoma (ATLL)

Diversity, Equity, Inclusion and Accessibility

Our medical center is dedicated to the idea that all people merit respect and access to high quality health care. Additionally, everyone deserves fair access to representation in clinical trials and research that will shape future medical care. We welcome and celebrate individuals of all races, ethnicities, social backgrounds, religion, gender, sex, age, ability, sexual orientation and national origin.

Member
Boston University
BU-BMC Cancer Center


Member
Boston University
Amyloidosis Center


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Sofoluwe A, Ferri G, Sloan JM, Caron J, Thomasson RR. Implementation of a Duffy antigen screening test order with interpretation guide to help optimize resource allocation at an urban safety-net hospital. Transfusion. 2025 Apr; 65(4):652-653.View Related Profiles. PMID: 40055154; DOI: 10.1111/trf.18205;
     
  2. Abdallah M, Arters F, Patel J, Edwards C, Lerner A, Petrocca F, Dockerty M, Fuller B, Godfrey A, Staron A, Sanchorawala V, Sloan JM, Bertrand K, Szalat R. Febrile neutropenia in patients with Duffy-null-associated neutrophil counts and multiple myeloma or AL amyloidosis. Blood Adv. 2024 Dec 10; 8(23):5935-5938.View Related Profiles. PMID: 39348709; PMCID: PMC11629209; DOI: 10.1182/bloodadvances.2024013453;
     
  3. Sanchorawala V, Barroso B, Shelton A, Goetz E, Mendelson L, Joshi T, Burke N, Sloan JM, Staron A. Defying the odds: 30 years in AL amyloidosis research-recent barriers to clinical trial enrollment. Blood Adv. 2024 Nov 26; 8(22):5826-5828.View Related Profiles. PMID: 39293090; PMCID: PMC11609355; DOI: 10.1182/bloodadvances.2024014262;
     
  4. Reifler KA, Francoeur Smith T, Bodanapu G, Fagan M, Bourque DL, Sloan JM. Indolent infections in patients with hematologic malignancy: A single-center experience screening for tuberculosis and strongyloidiasis prior to cytotoxic therapy in Boston. Leuk Res Rep. 2024; 22:100489.View Related Profiles. PMID: 39659827; PMCID: PMC11629577; DOI: 10.1016/j.lrr.2024.100489;
     
  5. Hibbs SP, Aiken L, Vora K, Mowete C, Merz LE, Apea V, Sloan JM, Lathan CS, Abel GA, Hantel A. Cancer Trial Eligibility and Therapy Modifications for Individuals With Duffy Null-Associated Neutrophil Count. JAMA Netw Open. 2024 Sep 03; 7(9):e2432475. PMID: 39259539; PMCID: PMC11391325; DOI: 10.1001/jamanetworkopen.2024.32475;
     
  6. Zheng R, Solomon A, DiLorenzo M, Rajendran I, Park J, Dhongade V, Garcia MA, Eberhardt RT, Sloan JM, Weinberg J, Klings ES. The Association of Anticoagulation Intensity with Outcomes in Hospitalized COVID-19 Patients. Adv Hematol. 2024; 2024:8838308.View Related Profiles. PMID: 38500844; PMCID: PMC10948223; DOI: 10.1155/2024/8838308;
     
  7. Sarosiek S, Lee MH, Doros G, Edwards CV, Quillen K, Brauneis D, Shelton AC, Sanchorawala V, Sloan JM. Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study. Transplant Cell Ther. 2023 Nov; 29(11):695.e1-695.e7.View Related Profiles. PMID: 37607644
     
  8. Halpin M, Lerner A, Sagar M, Govender P, Shah B, Weinberg J, Sarosiek S, Sloan JM. A prospective, single-center, randomized phase 2 trial of etoposide in severe COVID-19. medRxiv. 2023 Jun 06.View Related Profiles. PMID: 37333402; PMCID: PMC10274992; DOI: 10.1101/2023.06.05.23290969;
     
  9. Gustine JN, Szalat RE, Staron A, Joshi T, Mendelson L, Sloan JM, Sanchorawala V. Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes. Haematologica. 2023 Jun 01; 108(6):1680-1684.View Related Profiles. PMID: 36546447; PMCID: PMC10230421; DOI: 10.3324/haematol.2022.282264;
     
  10. Freydman J, Staron A, Hughes D, Sloan JM. Successful dasatinib therapy in newly diagnosed chronic myeloid leukemia in the setting of short bowel syndrome. J Oncol Pharm Pract. 2023 Sep; 29(6):1489-1493.View Related Profiles. PMID: 37157792
     
Showing 10 of 89 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 87 publications over 20 distinct years, with a maximum of 10 publications in 2019

YearPublications
20021
20041
20081
20091
20101
20115
20125
20133
20144
20155
20166
20177
20187
201910
20207
20217
20226
20234
20245
20251

Note: X.com has changed/limited the ability to embed tweets directly in external sites and we are investigating ways to restore that functionality in BU Profiles. In the meantime we are displaying a link to your x.com profile in the Websites section above.

2018 Boston University: Evans Clinician

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Education Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:

820 Harrison Ave
Boston MA 02118
Google Map


Sloan's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department
OSZAR »